Page 986 - Veterinary Immunology, 10th Edition

Eosinophilic Granuloma Complex, 344
VetBooks.ir Diagnosis of Type I Hypersensitivity, 345

Treatment of Type I Hypersensitivity, 346

Allergen-Specific Immunotherapy, 346

LEARNING OBJECTIVES

After reading this chapter, you should be able to:

• Define the hygiene hypothesis.
• Describe how the clinical signs of allergic disease depend in large part on the

route by which antigens (allergens) enter the body.
• Explain how the massive systemic release of inflammatory molecules by mast
cells and basophils causes anaphylaxis.

• List the significant species differences in anaphylaxis.
• Explain how and why animals commonly suffer from allergies to foods, inhaled
antigens, vaccines, or drugs.

• Discuss the evidence suggesting that atopic dermatitis is a very complex disease
or set of diseases, not all of which are mediated by IgE.
• Explain the mechanisms and treatment of pruritus.

• Explain the pathogenesis of allergic respiratory disease.
• Discuss the role of epithelial barrier dysfunction in atopic dermatitis.

• Describe the eosinophilic granuloma complex.
• Describe the appropriate treatment for atopic dermatitis.
• Explain the basic principles of treatment of allergic diseases.
• Explain how allergen-specific immunotherapy works.

• Define anaphylaxis, anaphylactoid, atopy, and asthma.

The development of type I hypersensitivity has long been
considered to result from the excessive release of inflammatory
mediators by mast cells, basophils, and eosinophils. The severity

and location of these reactions depends on the number and location
of these cells, the degree of sensitization of an animal, the amount

986